Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphoma.
MetadataShow full item record
After decades of intense research on genetic alterations in cancer and successful implementation of genetically-based targeted therapies, the field of cancer epigenetics is only beginning to be fully recognized. The discovery of frequent mutations in genes modifying the epigenome in diffuse large B-cell lymphoma (DLBCL) has highlighted the outstanding role of epigenetic deregulation in this disease. Identification of epigenetically-driven DLBCL subgroups and development of novel epigenetic drugs have rapidly advanced. However, further insights are needed into the biological consequences of epigenetic alterations and the possibility of restoring the aberrant epigenome with specific therapies to bring this treatment concept further into clinical practice. This review will summarize the main epigenetic changes found in DLBCL and their potential for precision medicine approaches.
The Institute of Cancer Research (Grant ID: Unspecified)
Version of record
Genetic Predisposition to Disease
Lymphoma, Large B-Cell, Diffuse
Molecular Targeted Therapy
Medicine (RMH Smith Cunningham)
License start date
Cancer treatment reviews, 2017, 59 pp. 132 - 137